Apellis Pharmaceuticals Inc's Chief Development Officer Sells Company Shares
On January 17, 2024, Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), sold 5,207 shares of the company's stock, according to a recent SEC Filing. The transaction was executed with the shares priced at $65.58 each, resulting in a total sale amount of $341,699.06.
Apellis Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases through the inhibition of the complement system at the level of C3.
Over the past year, the insider has sold a total of 12,956 shares of Apellis Pharmaceuticals Inc and has not made any purchases of the stock. The company's insider transaction history over the last year indicates a total of 68 insider sells and no insider buys.
Shares of Apellis Pharmaceuticals Inc were trading at $65.58 on the day of the insider's recent sale, giving the company a market capitalization of $7.57 billion.
The stock's price-to-GF-Value ratio stands at 0.45, with a GuruFocus Value of $144.67, indicating that Apellis Pharmaceuticals Inc is currently categorized as a Possible Value Trap, Think Twice based on its GF Value.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
